Cyclerion Therapeutics, Inc.
CYCN
$2.53
$0.062.43%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 830.93% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 830.93% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 830.93% | 284.76% | |||
| SG&A Expenses | 0.56% | -2.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.36% | -4.48% | |||
| Operating Income | 144.50% | 18.50% | |||
| Income Before Tax | 173.31% | 45.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 173.31% | 45.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 173.31% | 45.31% | |||
| EBIT | 144.50% | 18.50% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 172.85% | 45.66% | |||
| Normalized Basic EPS | 172.83% | 45.66% | |||
| EPS Diluted | 171.90% | 45.28% | |||
| Normalized Diluted EPS | 172.83% | 45.66% | |||
| Average Basic Shares Outstanding | 0.63% | 0.64% | |||
| Average Diluted Shares Outstanding | 0.63% | 0.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
